Stocks
Xeris Biopharma Holdings, Inc.XERS
NASDAQHealthcareBiotechnology$10.20
Price as of · delayed, not real-time
A commercial-stage biopharmaceutical company developing and commercializing therapies for endocrine and metabolic disorders, including its approved product for severe hypoglycemia. Its pipeline also targets epilepsy and other central nervous system conditions. Investors track the stock for its commercial execution and potential label expansions.
52W Range: $5.25-$11.42
Congressional Interest in Xeris Biopharma Holdings, Inc. (XERS)
No congressional trades have been disclosed for Xeris Biopharma Holdings, Inc. (XERS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading XERS?
No congressional trades found for this stock.